Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neural Ice
- Development stage
- Preclinical
- Lead developer
- Brixton Biosciences
- Modality
- Small Molecules
- Administration
- Infiltration, Perineural
01
Overview
Neural Ice is an investigational therapy developed by Brixton Biosciences designed for long-lasting pain control. It is administered as a single injection intended to provide highly targeted and enduring desensitization of pain in a specific area. The therapy aims to offer relief that lasts significantly longer than current local anesthetic methods, potentially addressing chronic or severe localized pain with fewer repeat interventions. The precise mechanism of action has not been fully disclosed, but it is described as a novel approach distinct from traditional local anesthetics[4].
- Brand names
- Neural Ice
- Other names
- Neural Ice
Beyond the preview
Go deeper on Neural Ice.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neural Ice.